HIGHLIGHTS
- who: Chu-Lin Chou et al. from the Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan have published the research: Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity, in the Journal: Nutrients 2022, 3759 of /2022/
- what: The study demonstrated that high fructose stimulation increased adipose size and triglyceride, MGL, ATGL, SCD1, ATF3, and PU.1 levels in adipocytes in_vitro; subsequently, PU.1 inhibitor treatment reduced triglyceride, SCD1, and PU.1.
- future: As for the role . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.